Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US58933Y1055
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BPD168
MRK
Merck & Co Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—General · THEMEFOLIO: $TF-77
NAME
Merck & Co Inc
ISIN
US58933Y1055
TICKER
MRK
MIC
XNYS
REUTERS
MRK.N
BLOOMBERG
MRK US
Mo., 20.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTR...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 20.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
So., 19.10.2025       Merck & Co.
US58933Y1055

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 18.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 18.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus sur...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 18.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to ch...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 16.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival (OS) for the treatment of patients with platinum-resistant recurrent ovarian cancer in all comers. The trial studied KEYTRUDA® (pembrolizumab), Merck’s...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that was virologically suppressed on bictegravir/emtricitab...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include: An oral presentation of weight and bo...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 types of cancer and multiple treatment settings from the company’s broad and differentiated portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 07.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Mark...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 06.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory d...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists an...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II o...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidas...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newb...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 15.09.2025       Merck & Co.
US58933Y1055

Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab. Raludotatug deruxtec...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 11.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) at the 6th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Vaccines, taking place in Lisbon, Portugal. T...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
So., 07.09.2025       Merck & Co.
US58933Y1055

Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 02.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment o...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 30.08.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results evaluating VERQUVO® (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction (HFrEF). The Phase 3 VICTOR trial comparing the efficacy of VERQUVO to placebo in patients with HFrEF without a recent worsening heart failu...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat a...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Merck & Co.
US58933Y1055

The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast can...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 25.08.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovasc...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey revealing significant gaps in pet owner adherence to flea and tick prevention and concerns among veterinarians, underscoring the need for year-r...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 18.08.2025       Merck & Co.
US58933Y1055

Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab deruxtecan is a specifically engineered, potential first-...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 13.08.2025       Merck & Co.
US58933Y1055

Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locall...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Merck & Co.
US58933Y1055

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025. "Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting decisively...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Me...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Merck & Co.
US58933Y1055

Approval is based on the results from phase III KEYNOTE-A18/ENGOT-cx11/GOG-30472 KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT)...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESS...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 10.07.2025       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to tre...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 10.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 09.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per Am...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 08.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda. Merck will share new scientific findings...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with c...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with c...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Merck & Co.
US58933Y1055

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 02.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercep...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 01.07.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists an...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 26.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend ENFLONSIA™ (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 24.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview of the company’s advancing HIV treatment and prevention research pipeline on July 17, 2025, at 9:00 a.m. ET. Investors, analysts, members of the m...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 23.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional clas...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 18.06.2025       Merck & Co.
US58933Y1055

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifina...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 13.06.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (C...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink